These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 23711387

  • 1. Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance.
    Liu D, Shi M, Duan C, Chen H, Hu Y, Yang Z, Duan H, Guo N.
    Mol Immunol; 2013 Nov; 56(1-2):104-12. PubMed ID: 23711387
    [Abstract] [Full Text] [Related]

  • 2. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [Abstract] [Full Text] [Related]

  • 3. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
    Chen YC, Li HY, Liang JL, Ger LP, Chang HT, Hsiao M, Calkins MJ, Cheng HC, Chuang JH, Lu PJ.
    Oncotarget; 2017 May 02; 8(18):29699-29710. PubMed ID: 27447863
    [Abstract] [Full Text] [Related]

  • 4. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
    Zhao Y, Wang Z, Jiang Y, Yang C.
    Cancer Lett; 2011 Dec 26; 313(1):54-63. PubMed ID: 21943825
    [Abstract] [Full Text] [Related]

  • 5. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C, Duan X, Xu L, Ye J, Zhao J, Liu Y.
    Breast Cancer Res Treat; 2012 Dec 26; 136(3):739-48. PubMed ID: 23117856
    [Abstract] [Full Text] [Related]

  • 6. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
    Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, Baselga J, Kufe D.
    Oncogene; 2014 Jun 26; 33(26):3422-31. PubMed ID: 23912457
    [Abstract] [Full Text] [Related]

  • 7. FOXO1A is a target for HER2-overexpressing breast tumors.
    Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV.
    Cancer Res; 2010 Jul 01; 70(13):5475-85. PubMed ID: 20551062
    [Abstract] [Full Text] [Related]

  • 8. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
    Yang L, Li Y, Shen E, Cao F, Li L, Li X, Wang X, Kariminia S, Chang B, Li H, Li Q.
    Int J Oncol; 2017 Nov 01; 51(5):1553-1562. PubMed ID: 29048656
    [Abstract] [Full Text] [Related]

  • 9. HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPß isoforms.
    Arnal-Estapé A, Tarragona M, Morales M, Guiu M, Nadal C, Massagué J, Gomis RR.
    Cancer Res; 2010 Dec 01; 70(23):9927-36. PubMed ID: 21098707
    [Abstract] [Full Text] [Related]

  • 10. MiRNA‑542‑3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation.
    Ma T, Yang L, Zhang J.
    Oncol Rep; 2015 Mar 01; 33(3):1215-20. PubMed ID: 25586125
    [Abstract] [Full Text] [Related]

  • 11. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.
    Chung SS, Giehl N, Wu Y, Vadgama JV.
    Int J Oncol; 2014 Feb 01; 44(2):403-11. PubMed ID: 24297508
    [Abstract] [Full Text] [Related]

  • 12. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS, Kang JC, Kim D, Ober RJ, Ward ES.
    Int J Cancer; 2015 Jul 15; 137(2):267-77. PubMed ID: 25471734
    [Abstract] [Full Text] [Related]

  • 13. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C, Yi X, Liu W, Han T, Liu Z, Ding Z, Zheng Z, Piao Y, Yuan J, Han Y, Xie M, Xie X.
    BMC Cancer; 2014 Nov 24; 14():869. PubMed ID: 25417825
    [Abstract] [Full Text] [Related]

  • 14. Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation.
    Shi Y, Fan X, Meng W, Deng H, Zhang N, An Z.
    Breast Cancer Res; 2014 Apr 02; 16(2):R33. PubMed ID: 24693969
    [Abstract] [Full Text] [Related]

  • 15. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
    Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N, Poghosyan Z, Nicholson RI, Barrett-Lee P, Gee J.
    BMC Cancer; 2012 Oct 06; 12():458. PubMed ID: 23039365
    [Abstract] [Full Text] [Related]

  • 16. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, Moran E, Zoppoli G, Pistoia V, Patrone F, Ballestrero A.
    PLoS One; 2010 Feb 02; 5(2):e9024. PubMed ID: 20126311
    [Abstract] [Full Text] [Related]

  • 17. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
    Ye XM, Zhu HY, Bai WD, Wang T, Wang L, Chen Y, Yang AG, Jia LT.
    BMC Cancer; 2014 Feb 26; 14():134. PubMed ID: 24571711
    [Abstract] [Full Text] [Related]

  • 18. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.
    Lim SJ, Lopez-Berestein G, Hung MC, Lupu R, Tari AM.
    Oncogene; 2000 Dec 14; 19(54):6271-6. PubMed ID: 11175341
    [Abstract] [Full Text] [Related]

  • 19. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
    Diermeier-Daucher S, Breindl S, Buchholz S, Ortmann O, Brockhoff G.
    Cytometry A; 2011 Sep 14; 79(9):684-93. PubMed ID: 21786419
    [Abstract] [Full Text] [Related]

  • 20. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.
    Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, Arteaga CL.
    Mol Cell Biol; 2008 Sep 14; 28(18):5605-20. PubMed ID: 18625725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.